Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 8/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 8/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | ATR | Q13535 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220465 | 0.87 | TLR7 (0.44) | JAK2TLR7TLR9TLR8PIK3CA | |
| SCHEMBL4213262 | 0.84 | PIK3CG (0.51) | JAK2TLR7TLR9TLR8PIK3CA | |
| SCHEMBL4045710 | 0.84 | TYRO3 (0.53) | JAK2TLR7TLR9TLR8ATR | |
| SCHEMBL4220286 | 0.81 | ADORA1 (0.52) | TLR7TLR9TLR8PIK3CAPIK3CB | |
| SCHEMBL4234405 | 0.80 | ADORA1 (0.51) | TLR7TLR9TLR8PIK3CAPIK3CB | |
| SCHEMBL4049232 | 0.80 | TLR7 (0.52) | TLR7TLR9TLR8PIK3CAPIK3CB | |
| SCHEMBL4050664 | 0.80 | TLR7 (0.47) | TLR7TLR9TLR8PIK3CAPIK3CB | |
| SCHEMBL4048549 | 0.79 | KDR (0.47) | TLR7TLR9TLR8ATRPIK3CA | |
| SCHEMBL4231695 | 0.78 | ADORA2A (0.50) | TLR7TLR9TLR8PIK3CA | |
| SCHEMBL4222169 | 0.77 | ADORA2A (0.54) | TLR7TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | claimed |
| US-20180125849-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2018-05-10 | — | — | US | disclosed |
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2016-10-20 | — | — | US | disclosed |
| US-8901134-B2 | Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders | NOVARTIS AG (CH) | 2014-12-02 | — | — | US | disclosed |
| US-20140235632-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2014-08-21 | — | — | US | disclosed |
| US-20140051698-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | NOVARTIS AG (CH) | 2009-05-21 | — | — | US | disclosed |
| EP-2026811-A1 | PYRAZOLO [3, 4-D]PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | Novartis AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134828-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | NOVARTIS AG (CH) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131457-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | JAK2 11/4885TLR7 1301/4885TLR9 1750/4885 |
| US-20140051698-A1 | Pyrazolo [3,4-D] Pyrimidine Derivatives Useful to Treat Respiratory Disorders | PIK3CA, JAK3, PDK1 | JAK2 11/4885TLR7 1301/4885TLR9 1750/4885 |
| US-20160303132-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | JAK2 11/4885TLR7 1301/4885TLR9 1750/4885 |
| US-20140235632-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | JAK2 11/4885TLR7 1301/4885TLR9 1750/4885 |
| US-20180125849-A1 | PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES USEFUL TO TREAT RESPIRATORY DISORDERS | PIK3CA, JAK3, PDK1 | JAK2 11/4885TLR7 1301/4885TLR9 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.